![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}
All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study
| URL | http://www.ic-hep.com/webcasts/apasl2015/THawkins/ |
|---|---|
| Speaker | Trevor Hawkins, MD |
Interferon Treatment in Hepatitis C: Necessary or Not in Future Aspects?
| URL | http://www.ic-hep.com/webcasts/apasl2015/DCrawford/ |
|---|---|
| Speaker | Darrell Crawford, MD |
The Differences in Antiviral Agents in the Treatment of Hepatitis B
| URL | http://www.ic-hep.com/webcasts/apasl2015/PMarcellin |
|---|---|
| Speaker | Patrick Marcellin, MD |
The impact of the treatment of HCV in developing Hepatocellular Carcinoma
| URL | http://www.ic-hep.com/webcasts/apasl2015/PKwo/ |
|---|---|
| Speaker | Paul Kwo, MD |
The Role of New Combination Therapies without Interferon for Chronic HCV Infection
| URL | http://www.ic-hep.com/webcasts/apasl2015/WChuang/ |
|---|---|
| Speaker | Wan-Long Chuang, MD |